Form 4: Syndax Pharmaceuticals Director Dennis Podlesak Acquires 50,000 Shares of Common Stock

Director Dennis Podlesak acquired 50,000 shares of Syndax Pharmaceuticals common stock on February 5, 2025, as part of a restricted stock unit award.

Summary

• On February 5, 2025, Dennis Podlesak, a director of Syndax Pharmaceuticals Inc., acquired 50,000 shares of common stock.
• The acquisition was part of a restricted stock unit (RSU) award.
• The price per share was $0.
• Following the transaction, Podlesak directly owns 191,763 shares of Syndax Pharmaceuticals Inc.
• The restricted stock units vest one year from the grant date, and the shares cannot be transferred or sold until separation from service, death, disability, or a change in control.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating a director's acquisition of shares through a restricted stock unit award. While insider ownership is generally viewed positively, the restricted nature of the shares tempers the enthusiasm.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Risks

• The restricted nature of the stock units means that the director cannot immediately sell or transfer the shares, which could limit their flexibility.

Future Outlook

The vesting of the restricted stock units is contingent upon continued service or certain events, aligning the director's interests with the long-term performance of the company.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The increased ownership by a director could positively influence shareholder confidence.

Key Dates